Christine Stephens

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Timothy A. Yap, Matthew Krebs, Sophie Postel‐Vinay et al. · Clinical Cancer Research · 2021 · 125 citations · Full text

Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)

Simon J. Crabb, Gareth Griffiths, Ellice Marwood et al. · Journal of Clinical Oncology · 2020 · 77 citations · Full text

Abstract CT026: Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers

Matthew Krebs, Juanita Lopez, Anthony B. El-Khoueiry et al. · Cancer Research · 2018 · 34 citations

Parp Inhibitor Olaparib, Pathology, Pharmacotherapy +18

Abstract LB-66: Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors .

Udai Banerji, Malcolm Ranson, Jan H.M. Schellens et al. · Cancer Research · 2013 · 26 citations

Pathology, Pharmacotherapy, Advanced Solid Tumors +16

Abstract A094: Phase I modular study of AZD0156, a first-in-class oral selective inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with olaparib (AToM Study, Module 1)

Wassim Abida, Yung Jue Bang, Louise Carter et al. · Molecular Cancer Therapeutics · 2018 · 17 citations

Molecular Biology, Pathology, Pharmacotherapy +18